← Back to Search

Aspirin and rivaroxaban from aspirin and clopidogrel for Coronary Artery Disease (SWAP-AC Trial)

Phase 4
Waitlist Available
Led By Dominick J Angiolillo, MD, PhD
Research Sponsored by University of Florida
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Willing and able to provide written informed consent
Above 18 years of age
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 30 days
Awards & highlights

SWAP-AC Trial Summary

This trial will compare the effects of two different treatments for people with atherosclerotic disease manifestations. The first treatment is the standard of care, which is called DAPT, and the second treatment is called DPI. DPI consists of aspirin plus rivaroxaban. The trial will compare the two treatments to see which is more effective in reducing ischemic recurrences.

Eligible Conditions
  • Coronary Artery Disease

SWAP-AC Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

SWAP-AC Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~30 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 30 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Maximal Platelet Aggregation (MPA%) by Light Transmittance Aggregometry (LTA)

SWAP-AC Trial Design

6Treatment groups
Experimental Treatment
Active Control
Group I: Aspirin and rivaroxaban from aspirin and ticagrelorExperimental Treatment2 Interventions
aspirin 81mg/qd plus rivaroxaban 2.5mg/bid for 30 days
Group II: Aspirin and rivaroxaban from aspirin and prasugrelExperimental Treatment2 Interventions
aspirin 81mg/qd plus rivaroxaban 2.5mg/bid for 30 days
Group III: Aspirin and rivaroxaban from aspirin and clopidogrelExperimental Treatment2 Interventions
aspirin 81mg/qd plus rivaroxaban 2.5mg/bid for 30 days
Group IV: Aspirin and prasugrelActive Control2 Interventions
aspirin 81 mg/qd plus prasugrel 10mg/qd for 30 days
Group V: Aspirin and ticagrelorActive Control2 Interventions
aspirin 81 mg/qd plus ticagrelor 60mg/bid for 30 days
Group VI: Aspirin and clopidogrelActive Control2 Interventions
aspirin 81 mg/qd plus clopidogrel 75mg/qd for 30 days
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
aspirin
2000
Completed Phase 4
~16940
rivaroxaban
2013
Completed Phase 4
~416490

Find a Location

Who is running the clinical trial?

University of FloridaLead Sponsor
1,333 Previous Clinical Trials
714,501 Total Patients Enrolled
44 Trials studying Coronary Artery Disease
31,682 Patients Enrolled for Coronary Artery Disease
Janssen, LPIndustry Sponsor
158 Previous Clinical Trials
304,868 Total Patients Enrolled
Dominick J Angiolillo, MD, PhDPrincipal InvestigatorUniversity of Florida
11 Previous Clinical Trials
1,672 Total Patients Enrolled
7 Trials studying Coronary Artery Disease
1,406 Patients Enrolled for Coronary Artery Disease

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~16 spots leftby Mar 2025